Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

Participants needed: 800
Trial details
Phase: Phase 4Age: 18-80Biological sex: AllType: InterventionalSponsor: Nabiqasim Industries (Pvt) LtdUpdated: Apr 17, 2026Locations: 2
Eligibility criteria

Patients of any gender [+5]

Patients with age less than 18 [+10]

Status: Not yet recruiting

REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat

Participants needed: 384
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Nabiqasim Industries (Pvt) LtdUpdated: Jan 20, 2026Duration: 3 Months
Eligibility criteria

Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD... [+2]

Acute Kidney Injury (AKI) without underlying chronicity [+5]

Status: Not yet recruiting

Primary Care ERectile Function Outcome Registry for Men

The PERFORM registry is a structured, real-world data platform designed to systematically capture patient characteristics, disease severity and treatment patterns of Erectile Dysfunction (ED) across Pakistan. By reflecting routine clinical practice, an ED registry provides valuable insights into the disease epidemiology, unmet needs, and variations in care across populations. It supports evidence-based decision-making, helps identifying early predictors, and inform guideline development, health policy, and personalized management strategies in male sexual health.

Participants needed: 255
Trial details
Age: 18+Biological sex: MaleType: ObservationalSponsor: Nabiqasim Industries (Pvt) LtdUpdated: Jan 21, 2026Duration: 12 Months
Eligibility criteria

Adult male above 18 years of age [+4]

If at any other PDE-5 inhibitor (sildenafil, tadalafil, vardenafil, avanafil) [+9]

Status: Recruiting

Resmiterom Efficacy & Safety in Patients With MASH

Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.

Participants needed: 165
Trial details
Phase: Phase 4Age: 18-75Biological sex: AllType: InterventionalSponsor: Nabiqasim Industries (Pvt) LtdUpdated: Dec 3, 2025Locations: 1
Eligibility criteria

• At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hype... [+4]

• History of drug addiction and alcoholism [+8]